U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H18N4O2S
Molecular Weight 366.437
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ILAPRAZOLE

SMILES

COC1=C(C)C(C[S+]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1

InChI

InChIKey=HRRXCXABAPSOCP-UHFFFAOYSA-N
InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)

HIDE SMILES / InChI
Molecular Formula C19H18N4O2S
Molecular Weight 366.437
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ilaprazole or IY-81149 (2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl -5-(1H-pyrrol-1-yl)-1H-benzimidazole, CAS 172152-36-2) is a proton pump inhibitor. Ilaprazole revealed the characteristics as a strong proton pump inhibitor, and its potency against gastric acid secretion was superior to that of the reference drug, omeprazole. Ilaprazole is approved in China and South Korea for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Recently it was discovered that ilaprazole inhibited the cancer growth by targeting T-cell-originated protein kinase (TOPK) both in vitro and in vivo.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 6.0 µM [IC50]
Inhibitor
8297
 111.0 µM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Approved
8429
Noltec

Approved Use

Ilaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers.

Launch Date

2007
Primary
Approved
8429
Noltec

Approved Use

Ilaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers.

Launch Date

2007
PubMed

PubMed

TitleDatePubMed
The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
2014 Sep
Patents

Patents

08592599
2

Sample Use Guides

In Vivo Use Guide
Short-term treatment of duodenal ulcer: Normally, 10 mg of adult is administered orally once a day. It is usually administered for up to 4 weeks. Short-term treatment of gastric ulcer: Normally, an adult dose of 10 mg is orally administered once a day. It is usually administered for 4 to 6 weeks. This medicine should be swallowed with water 1 hour before meals and should not be chewed or crushed. The recommended adult dosage of Ilaprazole is 5-20 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Ilaprazole exhibited potent inhibitory activities against the growth of HCT116 cells (IC50 = 40 uM) and ES-2 cells (IC50 = 33.2 uM). Ilaprazole (100 and 50 uM) induces apoptosis in ES-2 and HCT116 cells.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:02:02 GMT 2023
Edited
by admin
on Fri Dec 15 16:02:02 GMT 2023
Record UNII
776Q6XX45J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ILAPRAZOLE
INN   MART.   WHO-DD  
INN  
Official Name English
NOLTEC
Brand Name English
Ilaprazole [WHO-DD]
Common Name English
IY-81149
Systematic Name English
ilaprazole [INN]
Common Name English
2-((RS)-((4-METHOXY-3-METHYLPYRIDIN-2-YL)METHYL)SULFINYL)-5-(1H-PYRROL-1-YL)-1H-BENZIMIDAZOLE
Systematic Name English
ILAPRAZOLE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29723
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
Code System Code Type Description
SMS_ID
100000156496
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
CAS
172152-36-2
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
INN
8158
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
FDA UNII
776Q6XX45J
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
DRUG CENTRAL
3961
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
MESH
C119615
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID10870115
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
WIKIPEDIA
Ilaprazole
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
DRUG BANK
DB11964
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
ChEMBL
CHEMBL2106370
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
EVMPD
SUB130420
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
PUBCHEM
214351
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
NCI_THESAURUS
C65887
Created by admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Structure of Ilaprazole sodium
SALT/SOLVATE -> PARENT
POTASSIUM-TRANSPORTING ATPASE ALPHA CHAIN 1
TARGET -> INHIBITOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of 2-((5-(3-HYDROXYPYRROL-1-YL)-1H-BENZIMIDAZOL-2-YL)SULFANYLMETHYL)-3-METHYL-PYRIDIN-4-OL
METABOLITE -> PARENT
Structure of 2-(((4-METHOXY-3-METHYL-2-PYRIDINYL)METHYL)THIO)-N-PROPYL-1H-BENZIMIDAZOL-6-AMINE
METABOLITE -> PARENT
Structure of 2-(2-(HYDROXYSULFANYLMETHYL)-4-METHOXY-3-METHYL-PYRIDIN-1-IUM-1-YL)-5-PYRROL-1-YL-1H-BENZIMIDAZOLE
METABOLITE ACTIVE -> PRODRUG
Structure of DESOXY ILAPRAZOLE
METABOLITE -> PARENT
Structure of SULFONYL ILAPRAZOLE
METABOLITE -> PARENT
Structure of 1-(2-(((4-METHOXY-3-METHYL-2-PYRIDINYL)METHYL)THIO)-1H-BENZIMIDAZOL-6-YL)-1H-PYRROLE-2,3-DIOL
METABOLITE -> PARENT
Structure of ILAPRAZOLE METABOLITE M8
METABOLITE -> PARENT
Related Record Type Details
Structure of ILAPRAZOLE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966